BeiGene, Ltd. - Asset Resilience Ratio
BeiGene, Ltd. (ONC) has an Asset Resilience Ratio of 0.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ONC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how BeiGene, Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ONC asset base.
Liquid Assets Composition Over Time
This chart breaks down BeiGene, Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of BeiGene, Ltd. to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: BeiGene, Ltd. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
BeiGene, Ltd. Industry Peers by Asset Resilience Ratio
Compare BeiGene, Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for BeiGene, Ltd. (2014–2023)
The table below shows the annual Asset Resilience Ratio data for BeiGene, Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.04% | $2.60 Million | $5.81 Billion | -10.38pp |
| 2022-12-31 | 10.43% | $665.25 Million | $6.38 Billion | -15.84pp |
| 2021-12-31 | 26.27% | $2.24 Billion | $8.54 Billion | -32.10pp |
| 2020-12-31 | 58.36% | $3.27 Billion | $5.60 Billion | +35.74pp |
| 2019-12-31 | 22.62% | $364.73 Million | $1.61 Billion | -24.87pp |
| 2018-12-31 | 47.50% | $1.07 Billion | $2.25 Billion | -9.64pp |
| 2017-12-31 | 57.14% | $597.91 Million | $1.05 Billion | -12.02pp |
| 2016-12-31 | 69.16% | $280.66 Million | $405.81 Million | -1.60pp |
| 2015-12-31 | 70.76% | $82.62 Million | $116.76 Million | +13.88pp |
| 2014-12-31 | 56.88% | $30.50 Million | $53.62 Million | -- |
About BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more